Jan Tennvall
Overview
Explore the profile of Jan Tennvall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Warfvinge C, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, et al.
J Nucl Med
. 2024 May;
65(7):1070-1075.
PMID: 38724277
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the...
2.
Sundlov A, Sjogreen Gleisner K, Tennvall J, Ljungberg M, Warfvinge C, Holgersson K, et al.
Eur J Nucl Med Mol Imaging
. 2022 Apr;
49(11):3830-3840.
PMID: 35451612
Purpose: Radionuclide therapy with Lu-DOTATATE is well established for patients with advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule of 7.4 GBq at four occasions. However, this approach does...
3.
Ho A, Dedecjus M, Wirth L, Tuttle R, Inabnet 3rd W, Tennvall J, et al.
J Clin Oncol
. 2022 Feb;
40(17):1870-1878.
PMID: 35192411
Purpose: Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC)...
4.
Shahida B, Tsoumani K, Planck T, Modhukur V, Asp P, Sundlov A, et al.
Endocrine
. 2021 Dec;
75(3):856-864.
PMID: 34859391
Introduction: Treatment of Graves´ disease (GD) with radioiodine increases the risk of developing Graves´ ophthalmopathy (GO), and the link between thyroid and orbital tissue may be the presence of TSH-receptors....
5.
Roth D, Gustafsson J, Warfvinge C, Sundlov A, Akesson A, Tennvall J, et al.
J Nucl Med
. 2021 Jul;
63(3):399-405.
PMID: 34272319
Tumor dosimetry was performed for Lu-DOTATATE with the aims of better understanding the range and variation of the tumor-absorbed doses (ADs), how different dosimetric quantities evolve over the treatment cycles,...
6.
Sundlov A, Sjogreen-Gleisner K, Tennvall J, Dahl L, Svensson J, Akesson A, et al.
Neuroendocrinology
. 2020 Apr;
111(4):344-353.
PMID: 32259830
Introduction: The pituitary gland has a high expression of somatostatin receptors and is therefore a potential organ at risk for radiation-induced toxicity after 177Lu-DOTATATE treatment. Objective: To study changes in...
7.
Gretarsson S, Nygren A, Rosendahl A, Mylona N, Kjellen E, Jin Y, et al.
Acta Otolaryngol
. 2020 Jan;
140(4):337-343.
PMID: 31922436
Well characterized human cell lines are needed for preclinical treatment studies of anaplastic thyroid cancer (ATC). The aim was to establish, verify and characterize a panel of ATC cell lines....
8.
Lindgren O, Asp P, Sundlov A, Tennvall J, Shahida B, Planck T, et al.
Eur Thyroid J
. 2019 Jun;
8(2):64-69.
PMID: 31192144
Background: In Graves' disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit an immune response with an increase in...
9.
Sundlov A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, et al.
EJNMMI Phys
. 2018 Jul;
5(1):12.
PMID: 29974391
Background: Recently, Lu-dotatate therapy for neuroendocrine tumours has received regulatory approval. Dosimetry can be used to optimize treatment on an individual basis, but there is no international consensus as to...
10.
Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al.
Eur J Nucl Med Mol Imaging
. 2017 Mar;
44(9):1480-1489.
PMID: 28331954
Purpose: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving...